Problem of antibiotic resistance in urinary tract infection in ALdiwaniyah city, Iraq

Vian Hussam Almansi Alqani; Mudhfar Mohammed Meizel; Anmar Hameed Habeeb ALfuadi

doi:10.5455/rmj20221125095031

Abstract
Objective: To identify the most common UTI-causing bacteria in the study samples and to identify the most culture-sensitive antibiotics.
Methodology: The study was conducted at Adiwahiyah Teaching Hospital in Iraq's mid-Euphrates area from January 15, 2018 to September 2, 2019. The research included 400 Iraqi patients ages 2 to 85 with UTI symptoms.
Results: E. coli was sensitive to imipenem, meropenem, amikacin, and chloramphenicol. Klebsiella pneumoneae was sensitive to amikacin, imipenem, and meropenem. Enterobacter aerogenes was sensitive to imipenem, chloramphenicol, amikacin, and meropenem. Morganella morganii was sensitive to imipenem, meropenem, amikacin, and chloramphenicol. Trimethoprim-sulphamethoxazole, trimethoprim, tetracycline, and doxycycline were effective against Proteus mirabilis. Imipenem and meropenem were effective against Pantoea agglomerans. Amikacin, imipenem, and meropenem were effective against Providencia stuartii. Serratia marcescens was susceptible to trimethoprim-sulphamethoxazole, trimethoprim, amikacin, chloramphenicol, imipenem, and meropenem.
Conclusion: In the current study, in order of frequency, the most frequently isolated bacteria were E. coli, followed by Staph aureus. The study showed that the three best antibiotics for almost all isolated bacteria were imipenem, meropenem and amikacin with very minor exceptions.

Key words: Antibiotic resistance, urinary tract infection, UTI, Iraq.

ABOUT JOURNAL About Publisher Contact Us Editorial & Peer Review Process	POLICIES Privacy Policy Editorial Policy Author's Rights and Obligations Conflict of Interest Policy Plagiarism Policy Advertising Policy	STATEMENTS Terms of Use Author's Rights and Obligations Publication Ethics and Publication Malpractice Statement Protection of Research Participants (Statement On Human And Animal Rights) License Information

This is an open access journal which means that all content is freely available without charge to the user or his/her institution. Users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles in this journal without asking prior permission from the publisher or the author. This is in accordance with the Budapest Open Access Initiative (BOAI) definition of open access. The articles in Rawal Medical Journal are open access articles licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc-sa/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.

Indexed in Scopus, Web of Science, WHO Index Medicus IMEMR, Emromedex, Pakmedinet, ExtraMED and Tehqeeqat

How to cite this article

	Open Access and Peer-reviewed
Home Journal Issues Guide for Authors Editorial Board Aims & Scope About Journal News & Announcements